




BK Polyomavirus Genotypes in Two Patients after Hematopoietic Cell Transplant

Elizabeth A. Odegard,^a Heidi L. Meeds,^a Steven B. Kleiboeker,^b Assem Ziady,^c Anthony Sabulski,^d Sonata Jodele,^d Stella M. Davies,^d Benjamin L. Laskin,^e  Jason T. Blackard^a

^aDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

^bViracor-Eurofins Laboratories, Lee's Summit, Missouri, USA

^cDivision of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

^dDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

^eDivision of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

ABSTRACT BK polyomavirus (BKPv) infection can lead to nephropathy and hemorrhagic cystitis (HC). We evaluated BKPv genotypes in two individuals after hematopoietic cell transplant (HCT). The first case developed HC and was infected with genotype Ib-2, while the second did not develop HC and was infected with genotype Ia.

Human BK polyomavirus (BKPv) is a circular, double-stranded DNA virus of the *Polyomaviridae* family (genus *Betapolyomavirus*) that infects up to 90% of the general population by 10 years of age (1). While BKPv in immunocompetent individuals is rarely associated with clinical disease, during periods of immunosuppression, primary infection or reactivation of latent virus can lead to kidney (BKPv-associated nephropathy) and/or bladder (hemorrhagic cystitis [HC] and ureteral stenosis) injury (2, 3). There are no antiviral therapies approved for the treatment of BKPv infection. Thus, a comprehensive understanding of viral diversity is essential for the development of future therapeutic approaches (4).

We performed BKPv genotype analysis in two patients after hematopoietic cell transplant (HCT). One developed clinical disease, while the other did not. Subjects were enrolled in a prospective observational cohort and specimen repository after their HCT (5). Briefly, BKPv viruria and viremia were quantified in urine and blood samples from children and young adults undergoing HCT at Cincinnati Children's Hospital Medical Center (CCHMC) between April 2013 and May 2018. Nucleic acid testing for BKPv was performed on all plasma and urine samples at Viracor-Eurofins with a lower limit of quantification of 39 copies per milliliter. The CCHMC Institutional Review Board approved the study, and all patients or their parents/guardians provided written informed consent/assent. DNA was extracted using the Qiagen QIAamp UltraSens virus kit with centrifugation optimized for urine. The eluted DNA was digested with BamHI at 37°C for 60 min. The whole BKPv circular genome was amplified using the Qiagen long-range PCR kit with BK1731F and BK1739R primers and reaction conditions (6). Additionally, a nested PCR was performed to amplify a 1.5-kb region of the VP1 (7). PCR products were run on an agarose gel and purified with the QIAquick gel extraction kit. Next-generation sequencing (NGS) library preparation was performed using the NEB NEBNext Ultra II FS DNA library prep kit and sequenced with the setting of SR 1 × 51 bp on an Illumina HiSeq 1000 sequencer. PCR products were prepared separately, and the resulting reads were combined for samples from the same individuals. All tools were run with default parameters unless otherwise specified. The reads generated were run through FastQC; no reads were characterized as poor quality. Case 1 yielded a total of 2,268,367 reads with an average depth of 22,502×, while case 2 yielded 540,314 reads with an average depth of 5,360×.

Citation Odegard EA, Meeds HL, Kleiboeker SB, Ziady A, Sabulski A, Jodele S, Davies SM, Laskin BL, Blackard JT. 2021. BK polyomavirus genotypes in two patients after hematopoietic cell transplant. *Microbiol Resour Announc* 10:e01122-20. <https://doi.org/10.1128/MRA.01122-20>.

Editor Simon Roux, DOE Joint Genome Institute

Copyright © 2021 Odegard et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jason T. Blackard, jason.blackard@uc.edu.

Received 2 November 2020

Accepted 21 December 2020

Published 14 January 2021




FIG 1 Representative BKPyV genome sequences were downloaded from GenBank, and phylogenetic inference was performed in BEAST version 1.10.1 (10). Sequences for cases 1 and 2 are highlighted in red, while GenBank references are labeled by their accession number and country of origin. Genotypes 2, 3, and 4 are shown in blue. The nodes separating all genotypes are highlighted with closed circles.

The reads were mapped to the BKPyV reference genome sequence Dunlop (GenBank accession number [V01108](#)) within UGENE version 36.0, and the resulting consensus sequence was generated from each individual (8). For case 1, the genome sequence was 4,275 nucleotides long with a G+C content of 38%. For case 2, the genome sequence was 4,657 nucleotides long with a G+C content of 39%. The BKPyV genotype was initially assigned using the BKTyper tool (9). Phylogenetic inference was then performed using the Bayesian Markov chain Monte Carlo (MCMC) method in the Bayesian Evolutionary Analysis by Sampling Trees (BEAST) program version 1.10.1 (10) with a chain length of 500,000,000. After a 10% burn-in using Tree Annotator version 1.10.1, the maximum clade credibility tree was visualized in FigTree version 1.4.4.

Case 1 is a male who underwent allogeneic HCT at age 15 years for chronic granulomatous disorder. BKPyV viremia was first noted on day +11 after HCT, but he remained asymptomatic until HC developed on day +109. The urine BKPyV copy number at the time of symptom onset was 1.7×10^8 copies per milliliter, and the plasma BKPyV was 140,302 copies per milliliter.

Case 2 is a female who underwent myeloablative allogeneic HCT at age 21 years for

acute myelogenous leukemia. BKPyV was detected on day +28 with viremia of 900 copies per milliliter and viruria of 8.0×10^9 copies per milliliter. BKPyV viremia was also detected at month 2 (2,100 copies) and month 4 (2,900 copies). BKPyV viruria persisted during the first 4 months after transplant, peaking at month 1 and decreasing to 771,000 copies per milliliter by month 4.

Comparison to other BKPyV genome sequences confirmed that case 1 clustered with genotype Ib-2 references, while case 2 clustered with genotype Ia references (Fig. 1). Further understanding of viral pathogenesis and BKPyV diversity may define the mechanisms of kidney and bladder injury and inform the development of targeted therapeutic approaches for these high-risk patients.

Data availability. The raw sequence reads are available under BioProject accession number [PRJNA670723](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA670723) with reads available in the SRA under accession numbers [SRX9346189](https://www.ncbi.nlm.nih.gov/sra/SRX9346189) (case 2) and [SRX9346190](https://www.ncbi.nlm.nih.gov/sra/SRX9346190) (case 1). Consensus BKPyV genome sequences are available under GenBank accession numbers [MW023596](https://www.ncbi.nlm.nih.gov/genbank/MW023596) (case 2) and [MW023597](https://www.ncbi.nlm.nih.gov/genbank/MW023597) (case 1).

ACKNOWLEDGMENT

This work was funded by National Institute of Diabetes and Digestive and Kidney Diseases awards R01 DK125418 to B.L.L. and J.T.B. and K23 DK101600 to B.L.L.

REFERENCES

1. Knowles WA. 2006. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). *Adv Exp Med Biol* 577:19–45. https://doi.org/10.1007/0-387-32957-9_2.
2. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. 2002. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med* 347:488–496. <https://doi.org/10.1056/NEJMoa020439>.
3. Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RR, Jones RJ. 1995. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. *J Clin Oncol* 13:1103–1109. <https://doi.org/10.1200/JCO.1995.13.5.1103>.
4. Blackard JT, Davies SM, Laskin BL. 2020. BK polyomavirus diversity—why viral variation matters. *Rev Med Virol* 30:e2102. <https://doi.org/10.1002/rmv.2102>.
5. Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S, Lutzko C, Zhu X, Blackard JT, Jodele S, Lane A, Wallace G, Dandoy CE, Lake K, Duell A, Litts B, Seif AE, Olson T, Bunin N, Davies SM. 2019. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. *Clin Infect Dis* ciz1194. <https://doi.org/10.1093/cid/ciz1194>.
6. Chen Y, Sharp PM, Fowkes M, Kocher O, Joseph JT, Koralnik IJ. 2004. Analysis of 15 novel full-length BK virus sequences from three individuals: evidence of a high intra-strain genetic diversity. *J Gen Virol* 85:2651–2663. <https://doi.org/10.1099/vir.0.79920-0>.
7. Sahoo MK, Tan SK, Chen SF, Kapusinszky B, Concepcion KR, Kjelson L, Mallemapati K, Farina HM, Fernández-Viña M, Tyan D, Grimm PC, Anderson MW, Concepcion W, Pinsky BA. 2015. Limited variation in BK virus T-cell epitopes revealed by next-generation sequencing. *J Clin Microbiol* 53:3226–3233. <https://doi.org/10.1128/JCM.01385-15>.
8. Okonechnikov K, Golosova O, Fursov M, the UGENE team. 2012. Unipro UGENE: a unified bioinformatics toolkit. *Bioinformatics* 28:1166–1167. <https://doi.org/10.1093/bioinformatics/bts091>.
9. Martí-Carreras J, Mineeva-Sangwo O, Topalis D, Snoeck R, Andrei G, Maes P. 2020. BKTyper: free online tool for polyoma BK virus VP1 and NCCR typing. *Viruses* 12:837. <https://doi.org/10.3390/v12080837>.
10. Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and the BEAST 1.7. *Mol Biol Evol* 29:1969–1973. <https://doi.org/10.1093/molbev/mss075>.